title: β-Casein hydrolysate generated by the cell envelope-associated proteinase of Lactobacillus delbrueckii ssp. lactis CRL 581 protects against trinitrobenzene sulfonic acid-induced colitis in mice.
abstract: Lactobacillus delbrueckii ssp. lactis CRL 581, a thermophilic lactic acid bacterium used as a starter culture for the manufacture of several fermented dairy products, possesses an efficient proteolytic system that is able to release a series of potentially bioactive peptides (i.e., antihypertensive and phosphopeptides) from α- and β-caseins. Considering the potential beneficial health effects of the peptides released by L. delbrueckii ssp. lactis CRL 581 from milk proteins, the aim of this work was to analyze the anti-mutagenic and anti-inflammatory properties of the casein hydrolysates generated by the cell envelope-associated proteinase of this bacterium. The ability of α- and β-casein hydrolysates to suppress the mutagenesis of a direct-acting mutagen 4-nitroquinoline-N-oxide on Salmonella typhimurium TA 98 and TA 100 increased concomitantly with the time of casein hydrolysis. The anti-inflammatory effect of the β-casein hydrolysate was evaluated using a trinitrobenzene sulfonic acid (TNBS)-induced Crohn's disease murine model. The hydrolysate was administered to mice 10 d before the intrarectal inoculation of TNBS. The mice that received β-casein hydrolysate previously to TNBS showed decreased mortality rates, faster recovery of initial body weight loss, less microbial translocation to the liver, decreased β-glucuronidase and myeloperoxidase activities in the gut, and decreased colonic macroscopic and microscopic damage compared with the animals that did not receive this hydrolysate. In addition, β-casein hydrolysate exerted a beneficial effect on acute intestinal inflammation by increased interleukin 10 and decreased IFN-γ production in the gut. Our findings are consistent with the health-promoting attributes of the milk products fermented by L. delbrueckii ssp. lactis CRL 581 and open up new opportunities for developing novel functional foods.
authors.affiliation: Centro de Referencia para Lactobacilos-Consejo Nacional de Investigaciones Científicas y Técnicas, Chacabuco 145, 4000 San Miguel de Tucumán, Argentina.
authors.forename: M B
authors.initials: MB
authors.lastname: Espeche Turbay
authors.forename: A
authors.initials: A
authors.lastname: de Moreno de LeBlanc
authors.forename: G
authors.initials: G
authors.lastname: Perdigón
authors.forename: G
authors.initials: G
authors.lastname: Savoy de Giori
authors.forename: E M
authors.initials: EM
authors.lastname: Hebert
mesh_terms: D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology; D002364:Caseins / Q000494:pharmacology / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D005966:Glucuronidase / Q000378:metabolism; D048668:Lactobacillus delbrueckii / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D009152:Mutagenicity Tests; D009195:Peroxidase / Q000378:metabolism; D011492:Protein Hydrolysates / Q000494:pharmacology / Q000627:therapeutic use*; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology
chemical_list: D016587:Antimutagenic Agents; D002364:Caseins; D011492:Protein Hydrolysates; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D005966:Glucuronidase